Caris Life Sciences has filed to raise $100 million in a U.S. IPO, although the final amount may be higher. Click here to read more about CAI stock and the IPO.

Fourth quarterIn constant exchange rates, net sales increased by 6 percent mainly driven by Europe and APAC. Reported sales increased by 3 percent amounting to SEK 5,156 M (5,023).Book-to-bill ratio o ...

Commercialization building with large pharma contracts secured Further progress on next generation sequencing assays for DNA ...

Yet, I assess that Viking Therapeutics’s main growth vector will likely be imputed to its ability to commercialize and ...

and only fully powered randomised controlled trial of a multicomponent non-pharmacological intervention targeting sleep disturbance in people living at home with dementia to date. The study will ...

However, early work on stent-like tubular braided structure led to a more sophisticated construct that then later was coined as a flow diverter (FD) and found its way into clinical application ...

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory ...

Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives ...

Material and methods We conducted a double-blind randomised clinical trial stratified by risk factors ... for treatment of chlorhexidine 0.12% or placebo. Figure 1 shows the flow diagram of ...

Artificial intelligence and robotics are revolutionizing drug discovery by automating laboratory processes and enabling rapid ...